Northern Territory Perspectives on Heart Failure with Comorbidities - Understanding Trial Validity and Exploring Collaborative Opportunities to Broaden the Evidence Base

P. Iyngkaran, W. Majoni, A. Cass, Prashanthan Sanders, C. Ronco, S. Brady, N. Kangaharan, M. Ilton, D. L. Hare, M. C. Thomas

Research output: Contribution to journalReview ArticleResearchpeer-review

13 Citations (Scopus)


Congestive Heart Failure (CHF) is an ambulatory care sensitive condition, associated with significant morbidity and mortality, rarely with cure. Outpatient based pharmacological management represents the main and most important aspect of care, and is usually lifelong. This narrative styled opinion review looks at the pharmacological agents recommended in the guidelines in context of the Northern Territory (NT) of Australia. We explore the concept of validity, a term used to describe the basis of standardising a particular trial or study and the population to which it is applicable. We aim to highlight the problems of the current guidelines based approach. We also present alternatives that could utilise the core principles from major trials, while incorporating regional considerations, which could benefit clients living in the NT and remote Australia.

Original languageEnglish
Pages (from-to)536-543
Number of pages8
JournalHeart Lung and Circulation
Issue number6
Publication statusPublished - 1 Jun 2015
Externally publishedYes


  • Guidelines
  • Heart Failure
  • Indigenous Australians
  • Remote
  • Rural
  • Therapeutics

Cite this